This pharmaceutical company intends to start the first phase of the construction project of the preparation plant to support the development of the preparation CDMO business

Recently, Boten AG announced that the Company held the 20th interim meeting of the 4th Board of Directors on September 11, 2020 to consider and adopt the Bill on the Construction Project of the First Phase of the Preparation Plant.
it is learned that on August 29, 2019, The controlling subsidiary of Boten AG, Chongqing Boten Pharmaceutical Co., Ltd. ("Boten Pharmaceuticals"), was established, and the company officially launched the construction of the preparation CDMO platform to undertake the preparation CDMO business required for the drug development, clinical supply and market phase.
, Boten Pharmaceuticals has completed the construction of the core team, with more than 50 employees, of which research and development personnel accounted for 40%.
hardware facilities, Chongqing Research and Development Laboratory has been completed and put into operation in June this year, Shanghai Zhangjiang Research and Development Center renovation project has been officially started, is scheduled to be officially operational in November this year.
In order to support the company's preparation CDMO business planning and development, with preparation GMP production and release capacity, Boten Pharmaceuticals intends to invest about 278 million yuan in Chongqing Two Rivers New Area to start the first phase of the preparation plant construction project, in order to build the preparation CDMO service capacity, to undertake from IND to NDA and even commercial phase of the preparation outsourcing project, thereby enhancing the company's integrated delivery capacity.
according to the announcement, the proposed preparation plant project, located in Chongqing Two Rivers New Area Water and Soil Industrial Park, plans to build preparation GMP pilot workshop and supporting warehouses, power centers, chemicals depots, etc. a total of about 220,000 m2 One of the first phase of decoration area of about 188,000 m2, including 4 workshops and 1 reserved workshop, quality inspection office, integrated warehouse, power center, gate room, chemicals warehouse and other buildings and facilities, reserved area of 3180m2.
construction period of 22 months, the planned completion time is June 2022.
projects are financed entirely from self-financing.
CDMO (Contract Research and Development and Production Service) refers to the provision of process research and development services for intermediates and API of pharmaceuticals, including process research, optimization, analytical testing, preparation research, etc.
years, domestic CDMO enterprises have the basic conditions to take global orders, and in terms of cost, IP protection, rapid response capabilities and other advantages are obvious, so entered a rapid growth.
With the normalization of collection, consistent evaluation, drug market licensing system and other policies, will further force drug companies to innovate and develop, domestic new drug research and development continued to grow, and with the transfer of CDMO global production capacity, the demand for domestic preparation CDMO will continue to expand, the entire industry will bring opportunities, the market potential is huge.
research report shows that the current CDMO global industry average growth rate of 12%, the average domestic growth rate of nearly 20%, leading enterprises compound growth rate of more than 30%.
In addition to market capacity, the global market is currently expected to be $36 billion, the future space can grow to about 65 billion, the domestic market, the next five years from the current $2.6 billion to $7.5 billion, nearly triple the growth space.
industry said that the competitiveness of the CDMO industry mainly looks at two aspects, one is technology, including the optimization of the production process, amplification, the production and manufacturing capacity of innovative drugs, and the other is services, including supply chain management capabilities, service item breadth, registration consulting and other services.
with the increasing demand for integrated delivery capabilities, the ability to make a preparation CDMO will be an element of choice for many customers.
, the expansion of preparation capacity, in addition to the development of the propellant CDMO business, but also closely related to the company's overall profitability.
2020 semi-annual report, Boten shares achieved operating income of 925 million yuan in the first half of this year, up 48.16 percent year-on-year, and net profit of 131 million yuan, up 100.49 percent year-on-year.